Reig Jofre Future Health SLU

ODX, now Reig Jofre Future Health SLU, was established in 2013 as a spinoff of the Diagnostics department of Oryzon Genomics S. A., a world leader in Epigenetics. It is now a company of the Reig Jofre group whose strategy is developing and commercializing innovative molecular diagnostics for oncology that can reduce the cost of diagnostics and treatment algorithms while optimizing their outcome.\\Our first product is GynEC®-DX, a non-invasive in vitro diagnostic test for endometrial cancer that the company has designed, developed and brought to the market GynEC®-DX in collaboration with the pharmaceutical company Reig Jofre.\\ODX has on-going phase IV prospective clinical trials to validate the use of GynEC®-DX in asymptomatic populations with increased risk of endometrial cancer (endometrial polyps, Lynch syndrome).\\ODX also participates in the several collaborative R&D projects funded by the European Regional Development Fund (ERDF) in collaboration with the Spanish Ministry of Economy and Competitivity (MINECO) or the Spanish Ministry of Industry, Energy and Turism (MINETUR).\\ODX has been recognized as an innovative SME by the Spanish Ministry of Economy and Competitiveness. This label, created for small and medium enterprises (SMEs) officially recognizes our R&D efforts in the medical sector.

• Employees 3
• Founded 2013